What it is: A coenzyme found in every cell that powers energy production in mitochondria and fuels enzymes involved in DNA repair, gene expression, and cellular aging.
Research suggests: Randomized controlled trials confirm that NMN and NR supplementation reliably raises blood NAD+ levels; clinical longevity outcome data is still accumulating.
Best for: Longevity and cellular energy researchers
Key thing to know: NAD+ levels decline approximately 50% between ages 20 and 60; oral precursors (NMN or NR) and IV infusion are the most studied delivery approaches for raising levels.
What is NAD+?
NAD+ (nicotinamide adenine dinucleotide) is not a peptide but a coenzyme — a small molecule from vitamin B3 (niacin) that acts as an essential cofactor in hundreds of metabolic reactions in every cell. It appears in the Pepvela library because it is widely researched alongside peptide protocols for longevity, metabolic health, and recovery, and underpins current aging biology research.
NAD+ exists in two interconvertible forms — NAD+ (oxidized) and NADH (reduced) — whose ratio reflects the cell's energy state. It serves as a carrier in the electron transport chain, generating ATP in the mitochondria, and as a required substrate for enzymes including sirtuins (SIRT1–7) and PARPs (poly ADP-ribose polymerases), which govern gene expression, DNA repair, and stress responses.
Across species and human studies, cellular NAD+ levels decline substantially with age — roughly 50% from early adulthood to middle age in multiple tissues. Researchers in longevity consider this a central driver of age-related mitochondrial dysfunction, reduced DNA repair, and metabolic deterioration. Raising NAD+ via precursors (NMN, nicotinamide mononucleotide, or NR, nicotinamide riboside) or IV infusion is an active research area.
How it works.
In research, the proposed mechanism has several parts.
Two mechanisms: NAD+ operates through two primary and distinct mechanisms relevant to longevity and metabolic research. The first is its role as an electron carrier in the mitochondrial electron transport chain (ETC). In cellular respiration, NAD+ accepts electrons from metabolic substrates and becomes NADH, then donates those electrons to the ETC to drive ATP synthesis.
Energy production: When NAD+ levels decline, this energy production process becomes less efficient, a key contributor to age-related fatigue, reduced metabolic rate, and mitochondrial dysfunction.
Sirtuins and PARPs: The second mechanism is its role as a required substrate for sirtuin enzymes (SIRT1–7) and PARP enzymes. Sirtuins are NAD+-dependent deacetylases that regulate gene expression, mitochondrial biogenesis, inflammation, and cellular stress responses. They cannot function without NAD+ as a co-substrate, consuming it in the process of each catalytic cycle.
DNA repair: PARPs are DNA damage response enzymes that also consume NAD+ in repairing single-strand DNA breaks. As DNA damage accumulates with age, PARP activity increases, which accelerates NAD+ depletion and creates a feedback loop of increasing cellular dysfunction.
Precursors (NMN, NR): NMN and NR are oral precursors that enter NAD+ biosynthesis pathways inside cells and raise intracellular NAD+ concentrations. IV NAD+ infusion bypasses the need for intracellular conversion, delivering the coenzyme directly, resulting in faster, more pronounced NAD+ elevation but requiring clinical administration. Both approaches are currently being studied in human trials examining metabolic, cognitive, and aging-related outcomes.
What the research shows.
The research evidence breaks down as follows.
Preclinical evidence: The preclinical evidence for NAD+ restoration is among the strongest in the longevity research field. Preclinical studies across multiple species have examined NAD+ elevation through NMN, NR, or precursor supplementation in relation to mitochondrial function, lifespan-associated markers, metabolic parameters, muscle function, and age-related cognitive-decline markers. These findings are reproducible and mechanistically well-characterized.
Human evidence: In humans, the evidence has advanced meaningfully in recent years. Multiple randomized, double-blind, placebo-controlled trials have confirmed that oral NMN and NR supplementation reliably elevates blood NAD+ levels, establishing proof-of-target engagement. Studies in older adults have shown improvements in muscle function, endurance, and some metabolic markers at elevated NAD+ levels.
IV use: IV NAD+ infusion is used clinically in some longevity and functional medicine settings, with observational reports of acute energy and cognitive improvements, though rigorous clinical trial data for IV infusion outcomes remains limited compared to oral precursor data.
The evidence gap: Large, long-term randomized controlled trials examining hard longevity outcomes (mortality, disease incidence, functional decline) are currently underway but have not yet reported results. The evidence base is strong enough to establish biological plausibility and target engagement, with emerging but not yet definitive human outcome data, hence the Moderate rating rather than Strong.
Biomarkers to review first.
These markers provide relevant baseline context for metabolic health, insulin sensitivity, inflammation, and systemic stress before building a NAD+ restoration protocol.
What it's commonly researched with.
NAD+ restoration is frequently combined with other longevity and metabolic compounds in research protocols targeting cellular energy, mitochondrial function, and healthy aging.